TCR2 Therapeutics Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCR2 Therapeutics stock.
View analyst ratings for TCR2 Therapeutics or view top-rated stocks.

Wall Street analysts have given TCR2 Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TCR2 Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

TCR2 Therapeutics Inc. (NASDAQ:TCRR) issued its earnings results on Thursday, May, 13th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.05.
View TCR2 Therapeutics' earnings history.

TCR2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TCRR stock has increased by 124.6% and is now trading at $19.27.
View which stocks have been most impacted by COVID-19.

8 analysts have issued 12 month target prices for TCR2 Therapeutics' stock. Their forecasts range from $34.00 to $56.00. On average, they expect TCR2 Therapeutics' stock price to reach $45.14 in the next twelve months. This suggests a possible upside of 134.3% from the stock's current price.
View analysts' price targets for TCR2 Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to TCR2 Therapeutics include Bavarian Nordic A/S (BVNRY), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), Rubius Therapeutics (RUBY), Revolution Medicines (RVMD), Editas Medicine (EDIT), NanoString Technologies (NSTG), bluebird bio (BLUE), Kymera Therapeutics (KYMR), Sorrento Therapeutics (SRNE), Ocugen (OCGN), Replimune Group (REPL), Sangamo Therapeutics (SGMO) and AlloVir (ALVR).
View all of TCRR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at a price of $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

TCR2 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.04%), Victory Capital Management Inc. (3.23%), JPMorgan Chase & Co. (1.72%), Rothschild & Co. Asset Management US Inc. (1.47%), Geode Capital Management LLC (1.19%) and Dimensional Fund Advisors LP (0.92%). Company insiders that own TCR2 Therapeutics stock include Mayur Ian Somaiya, Morana Jovan-Embiricos, Neil W Gibson and Robert Hofmeister.
View institutional ownership trends for TCR2 Therapeutics.

TCRR stock was sold by a variety of institutional investors in the last quarter, including Rothschild & Co. Asset Management US Inc., Perceptive Advisors LLC, Sei Investments Co., Granite Point Capital Management L.P., Fred Alger Management LLC, Nuveen Asset Management LLC, Credit Suisse AG, and IndexIQ Advisors LLC. Company insiders that have sold TCR2 Therapeutics company stock in the last year include Mayur Ian Somaiya, and Robert Hofmeister.
View insider buying and selling activity for TCR2 Therapeutics or view top insider-selling stocks.

TCRR stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., BlackRock Inc., Dimensional Fund Advisors LP, Tekla Capital Management LLC, JPMorgan Chase & Co., Renaissance Technologies LLC, Citigroup Inc., and Altium Capital Management LP.
View insider buying and selling activity for TCR2 Therapeutics or or view top insider-buying stocks.

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TCRR stock can currently be purchased for approximately $19.27.

TCR2 Therapeutics has a market capitalization of $734.90 million. The company earns $-47,600,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis.

TCR2 Therapeutics employs 118 workers across the globe.

The official website for TCR2 Therapeutics is www.tcr2.com.

TCR2 Therapeutics is headquartered at 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142.

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]